- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03080428
Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer (OPTIGEN)
Prospective Multicenter Randomized Study Assessing Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer With Uncertainty on the Indication of Chemotherapy Using Standard Assessments.
The need/benefit of adjuvant chemotherapy could be negligible for a certain category of patient with newly diagnosed unilateral non metastatic breast cancer. Physicians are sometimes divided between the administration of adjuvant treatment and no administration when the risk of distant relapse at 10 years is around 10% with uncertainty and a theoretical benefit of chemotherapy is less than 5% at 10 years according to guidelines in use in the center.
Several genomic tests have been developed this last decade. These tests use a sample of breast cancer tissue to analyze the activity of a group of genes. Knowing whether certain genes are present or absent, overly active or not active enough, can help physicians predict the risk of recurrence.
In addition to standard pathological characteristics, a genomic test could be helpful in making treatment decisions, such as whether or not chemotherapy should be part of the treatment plan. First generation prognostic tests are currently widely used worldwide to guide decision making regarding adjuvant chemotherapy (OncotypeDX™ Mammaprint®). Prognostic tests have reached a level of evidence 1A, with the results of the prospective randomized trial "Mindact". In the "Mindact" trial, among women with early-stage breast cancer who were at high clinical risk and low genomic risk for recurrence, the receipt of no chemotherapy on the basis of the 70-gene signature led to a 5-year rate of survival without distant metastasis that was 1.5 percentage points lower than the rate with chemotherapy. Given these findings, approximately 46% of women with breast cancer who are at high clinical risk might not require chemotherapy. The health-economic value of such signatures in the general population of patients with localized breast cancer appears very low at current costs.
Meanwhile, next generation prognostic signatures have been developed that have integrated clinical parameters and suggest high added value beyond all standard and traditional characteristics including tumor burden, grade, Estrogen Receptor (ER) and Progesterone Receptor (PR), Her2, age and also standard assessment of proliferation.
In this study, the clinical utility of genomic tests (Endopredict®, Prosigna®, OncotypeDX®, Mammaprint® assay) defined as impact on chemotherapy decision in the adjuvant setting in patients with ER-positive, Her2-negative early breast cancer with uncertainty on the indication of chemotherapy using standard assessments will be compared.
Study Overview
Status
Intervention / Treatment
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Woman, Age ≥ 18 years;
- Performance status 0 or 1 (according to World Health Organization criteria);
- Patient with newly diagnosed, unilateral, localized, histologically confirmed, invasive breast cancer; Note: Multicentric/multifocal tumors are allowed provided a maximum of 3 lesions are present, and all are ER > 10% or Allred ≥ 4, Her2-negative (genomic test will be performed on the lesion considered the most pertinent by the multidisciplinary team)
- Fully operated breast cancer including complete resection of breast tumor and adequate axillary surgery;
- Available surgical material (formalin-fixed, paraffin-embedded) for genomic test evaluation;
- ER-positive by immuno-histochemical (>10% cells stained or Allred Score≥4);
- HER2-negative by IHC (score 0 or 1+) and/or fluorescence in situ hybridization/silver in situ hybridization/chemiluminescent in situ hybridization ;
Uncertainty regarding the toxicity/benefit of adjuvant chemotherapy, outlined in the following situations:
- Grade 1: pT3 or 1-3 node positive
- Grade 2: pT1 pN0 but high proliferation (Ki67 >20%) or lympho-vascular emboli, or 1-3 node positive
- Grade 2 : pT2 pN0
- Grade 3: pT1 pN0
- Adequate renal, hepatic, cardiac and hematopoietic functions for a chemotherapy administration;
- Willingness and ability to comply with scheduled visits as well as with test results and chemotherapy decision according to the latest;
- Signed informed consent and Health insurance coverage.
Exclusion Criteria:
- Non operable, bilateral, locally advanced, T4 or metastatic breast cancer;
- HER2 Overexpression, as assessed by 3+ IHC or FISH/SISH/CISH amplification;
- Diagnosis of any previous malignancy within the last 5 years, except for adequately treated basal cell carcinoma, or squamous cell skin carcinoma, or in situ cervical carcinoma;
- Any previous systemic or locoregional treatment for the present breast cancer;
- Documented inherited predisposition with BRCA1/2 or TP53 mutation;
- Previous hormone replacement therapy (HRT) stopped less than 2 weeks before surgery;
- Previous treatment for the present breast cancer;
- Person unable to give informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Endopredict®
genomic test Endopredict® realized on surgery tumour samples
|
genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
|
ACTIVE_COMPARATOR: Prosigna®
genomic test Prosigna® realized on surgery tumour samples
|
genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
|
ACTIVE_COMPARATOR: OncotypeDX®
genomic test OncotypeDX® realized on surgery tumour samples
|
genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
|
ACTIVE_COMPARATOR: Mammaprint® assay
genomic test Mammaprint® assay realized on surgery tumour samples
|
genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of genomic tests clinical utility
Time Frame: At the end of the inclusion period: 12 months
|
Pairwise comparisons between genomic tests in terms of percentage of changes between initial adjuvant chemotherapy decision and final receipt of chemotherapy (yes/no)
|
At the end of the inclusion period: 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Distant disease-free survival in patients who do not receive chemotherapy
Time Frame: 5 years
|
5-year distant disease-free survival among the pooled cohort of patients who did not receive chemotherapy
|
5 years
|
Distant disease-free survival in patients who do not receive chemotherapy based on genomic test result.
Time Frame: 5 years
|
5-year distant disease-free survival in patients who did not receive chemotherapy based on genomic test result
|
5 years
|
Reason for discordant final decision when they occur
Time Frame: 12 months
|
Number of decision changes according to the test results.
Physicians' and patients' reasons for "non-compliance" with the test's results will be recorded (a threshold at 10% 10 year distant recurrence risk will be chosen)
|
12 months
|
Feasibility of test in terms of time interval.
Time Frame: 12 months
|
Time interval between prescription and result of the test (% < 10 days)
|
12 months
|
differences in results between local and central reading of ER, PR, Her2 and Ki67
Time Frame: 12 months
|
A comparison with local evaluation of HR, Her2, and ki-67 will be made
|
12 months
|
Change of therapy based on the genomic test findings in a virtual tumour board
Time Frame: 12 months
|
Choice of therapy in a virtual tumour board based on the genomic test findings
|
12 months
|
Evaluation of the cost effectiveness of genomic tests
Time Frame: 5 years
|
Medico-economic impact based on results of the "Optisoin 01" study
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Roman Rouzier, MD, Institut Curie
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UC-0140/1620
- 2016-A01731-50 (OTHER: Id-RCB)
- UCBG 2-15 (OTHER: UNICANCER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ER-positive Her2-negative Early Breast Cancer
-
Masonic Cancer Center, University of MinnesotaActive, not recruitingTriple Negative Breast Cancer | HER2-positive Breast Cancer | TN ER-/PR-/HER2- Breast Cancer | ERany/PRany/HER2+ Breast CancerUnited States
-
Clovis Oncology, Inc.TerminatedBreast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ERUnited States
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Jules Bordet InstituteHoffmann-La Roche; Breast International Group; Institut Curie; International Drug...SuspendedHER2-positive Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast Cancer | Node-negative Breast CancerKorea, Republic of, France, Israel, Belgium, Switzerland, Australia
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
AstraZenecaRecruitingER-Positive HER2-Negative Breast CancerUnited States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
-
Jennifer Lee Caswell-JinNational Cancer Institute (NCI); QED Therapeutics, Inc.TerminatedBreast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast CancerUnited States
-
Abramson Cancer Center at Penn MedicineRecruitingBreast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | ER Positive Breast CancerUnited States
-
AstraZenecaActive, not recruitingER-Positive HER2-Negative Breast CancerAustria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
-
Organisation for Oncology and Translational ResearchUnknownLetrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal WomenER Positive, HER2 Negative Breast CancerChina
Clinical Trials on Genomic test
-
UNICANCERMyriad Genetics, Inc.Completed
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingProstate CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Solid Neoplasm | Breast Carcinoma | Lung Carcinoma | Colorectal Carcinoma | Ovarian Carcinoma | Pancreatic Carcinoma | Prostate CarcinomaUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States, Puerto Rico
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruitingHereditary DiseasesChina
-
University of California, San FranciscoEnrolling by invitationFetal Structural AnomaliesUnited States
-
The Cleveland ClinicCompletedHypertrophic Cardiomyopathy | Genetic Disease | Gene Product Sequence VariationUnited States
-
University of California, San FranciscoRecruitingPregnant Individuals Requesting Standard MicroarrayUnited States
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruitingNeonatal HyperbilirubinemiaChina
-
Odense University HospitalRecruiting